Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11595320-000000000-00000PMID 21895039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Summary of the article: Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 1557-1559].

  2012cited by this paper
• Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

  2010cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

  2009cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

  2009cited by this paper
• In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans

  2009cited by this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.

  2008cited by this paper
• Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery

  2008cited by this paper
• Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  2008cited by this paper
• Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

  2008cited by this paper
• A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.

  2008cited by this paper
• Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.

  2007cited by this paper
• Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

  2007cited by this paper
• Venous thromboembolism: disease burden, outcomes and risk factors

  2005cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

  2005cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor

  2005cited by this paper
• In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor

  2005cited by this paper
• The Epidemiology of Venous Thromboembolism

  2003cited by this paper
• Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).

  2003cited by this paper
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

  2003cited by this paper
• Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

  2001cited by this paper
• The Epidemiology of Venous Thromboembolism in the Community

  2001cited by this paper
• Biology of renal aging in humans.

  2000cited by this paper
• Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey.

  1998cited by this paper
• Estimating population kinetics.

  1982cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Perioperative management of colorectal surgical patients receiving a direct oral anticoagulant: a scoping review, particular emphasis on procedure-specific risks, and pharmacogenomics

  2026cites this paper
• No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.

  2026cites this paper
• Absorption and anticoagulant management of rivaroxaban in patients with short bowel syndrome.

  2025cites this paper
• Comprehensive and robust stability-indicating reversed phase high performance liquid chromatography (RP-HPLC) method for Rivaroxaban: synergistic integration of infrared spectroscopy and clinical pharmacology insights

  2025cites this paper
• Anticoagulation in obese patients: challenges and strategies

  2025cites this paper
• Optimized and Validated Stability-Indicating RP-HPLC Method for Comprehensive Profiling of Process-Related Impurities and Stress-Induced Degradation Products in Rivaroxaban (XARELTO)®

  2025cites this paper
• Association of rivaroxaban plasma trough concentrations with clinical characteristics and outcomes

  2025cites this paper
• Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs

  2024cites this paper
• Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial

  2024cites this paper
• Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation

  2024cites this paper
• Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity

  2024cites this paper
• Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis

  2024cites this paper
• Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation

  2024cites this paper
• Pharmacodynamic Study of Parallel Groups Comparing the Effect of Rivaroxaban 20 Mg (Laboratorios Leti, S.A.V.) vs Rivaroxaban 20 Mg (Bayer Laboratories) on Prothrombin Time

  2024cites this paper
• A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL

  2024cites this paper
• Variability of the anticoagulant effect according to body weight in patients treated with direct oral anticoagulants

  2024cites this paper
• Rapid Determination of Rivaroxaban by Using Terahertz Metamaterial Biosensor

  2024cites this paper
• Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban

  2023cites this paper
• 抗血栓药物拜瑞妥的远红外光谱研究

  2023cites this paper
• Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies

  2023cites this paper
• Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation

  2023influential citation
• Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study

  2023cites this paper
• One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations.

  2023cites this paper
• Population Pharmacokinetics of Rivaroxaban in Real‐World Patients

  2023cites this paper
• Using the Method of Molecular Modeling and Docking to Estimate the Potential Danger of Side Effects of Therapeutic Agents Used with Cardiac Amyloidosis

  2023cites this paper
• Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy

  2023cites this paper
• Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombi-Insights from a Swiss Multicenter Registry.

  2023cites this paper
• Poor Correlation of Rivaroxaban Concentration with the Routine Coagulation Screening Test in Chinese Patients with Atrial Fibrillation

  2023cites this paper
• Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation.

  2023cites this paper
• Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis

  2023cites this paper
• Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations

  2023cites this paper
• Efficacy and safety of rivaroxaban in prevention and therapy of thromboembolic events in patients with nonvalvular atrial fibrillation

  2023cites this paper
• Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review

  2023cites this paper
• An extension of biorelevant fed-state dissolution tests to clinical pharmacokinetics - a study on gastrointestinal factors influencing rivaroxaban exposure and efficacy in atrial fibrillation patients.

  2023cites this paper
• Intravenous Thrombolytic Therapy for Treatment of Acute Ischemic Stroke in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.

  2022cites this paper
• An integration strategy combined progressive multivariate statistics with anticoagulant activity evaluation for screening anticoagulant quality markers in Chinese patent medicine.

  2022cites this paper
• Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice.

  2022cites this paper
• Clinical features and posttreatment monitoring of dogs administered rivaroxaban (2018-2020): 19 cases.

  2022cites this paper
• Determination of the solubility of rivaroxaban (anticoagulant drug, for the treatment and prevention of blood clotting) in supercritical carbon dioxide: Experimental data and correlations

  2022cites this paper
• A ten-year review of the impact of the transition from warfarin to direct oral anticoagulant - Has venous thromboembolism treatment become safer?

  2022cites this paper
• Protective effects of rivaroxaban against cisplatin-induced testicular damage in rats: Impact on oxidative stress, coagulation, and p-NF-κB/VCAM-1 signaling.

  2022cites this paper
• Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events

  2022cites this paper
• Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation

  2022cites this paper
• Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review

  2022cites this paper
• Comparing Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Extreme Obesity

  2022cites this paper
• Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients

  2022cites this paper
• A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation

  2022cites this paper
• Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin

  2022cites this paper
• Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients

  2022cites this paper
• "Various approaches to postmarketing drug safety monitoring"

  2022cites this paper
• Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study

  2022cites this paper
• Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism

  2022cites this paper
• Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation

  2022cites this paper
• Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban

  2021influential citation
• Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area

  2021cites this paper
• Anticoagulants in the Management of Pulmonary Embolism

  2021cites this paper
• Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations

  2021cites this paper
• Review of Medical Therapies for the Management of Pulmonary Embolism

  2021cites this paper
• Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study

  2021cites this paper
• Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome

  2021cites this paper
• Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation

  2021cites this paper
• Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study

  2021cites this paper
• Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration

  2021cites this paper
• The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations

  2021cites this paper
• Synthesis, Characterization, and Properties of Rivaroxaban New Crystalline Forms

  2021cites this paper
• Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions

  2021cites this paper
• Commonly Prescribed Medications that Affect Clotting: A Comprehensive Overview

  2021cites this paper
• Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.

  2021cites this paper
• Ischaemic stroke in anticoagulated patients with atrial fibrillation

  2021cites this paper
• Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population

  2021cites this paper
• Drug-drug interactions with direct oral anticoagulants: practical recommendations for clinicians.

  2021cites this paper
• The importance of use of appropriate anticoagulant in atrial fibrillation after gastric bypass surgery

  2021cites this paper
• Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review

  2021cites this paper
• 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.

  2021cites this paper
• Quantitative detection of rivaroxaban based on far-IR absorbance spectroscopy and Raman spectroscopy

  2021cites this paper
• Expedition of sulfur‐containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update

  2021cites this paper
• Prophylactic efficacy of two anticoagulant drugs, heparin calcium and rivaroxaban, on venous thrombosis after knee arthroplasty

  2020cites this paper
• Prescribing Pattern of Oral Anticoagulants in Patients With Obesity

  2020cites this paper
• Simultaneous determination of Rivaroxaban and TAK-438 in rat plasma by LC-MS/MS: application to pharmacokinetic interaction study.

  2020cites this paper
• Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.

  2020cites this paper
• Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation.

  2020cites this paper
• The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations

  2020cites this paper
• Challenges and Opportunities in the Pharmacological Treatment of Acute Venous Thromboembolism in Children

  2020cites this paper
• Morbidly Obese Patient on Rivaroxaban Presents With Recurrent Upper Extremity Deep Vein Thrombosis: A Case Report

  2020influential citation
• Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients.

  2020cites this paper
• A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population.

  2020cites this paper
• Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis

  2020cites this paper
• [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].

  2020cites this paper
• Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.

  2020cites this paper
• Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

  2020cites this paper
• Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants

  2020cites this paper
• Treatment of venous thromboembolism in elderly patients in the era of direct oral anticoagulants.

  2020cites this paper
• Quantitative analysis of direct oral anticoagulant rivaroxaban by terahertz spectroscopy.

  2020cites this paper
• Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation

  2020cites this paper
• Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials

  2020cites this paper
• Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio.

  2020cites this paper
• Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review.

  2020cites this paper
• Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism

  2020cites this paper
• Rivaroxaban – farmakologický profi l

  2020cites this paper
• Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban

  2019cites this paper